Urine sensor could replace needles for cancer monitoring
NCT ID NCT01693861
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether special sensors could measure changes in urine chemicals to track how chemotherapy affects cancer growth. Researchers collected daily urine samples from 16 people with metastatic colorectal cancer before and after starting chemotherapy. The goal was to see if this non-invasive method could replace frequent blood tests or scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple urine test to monitor how well chemotherapy is working without invasive procedures.
- What could go wrong
- This is a very small, early observational study with only 16 participants. The urine sensor technology is still experimental and may not prove reliable enough for clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Paul Brousse Hospital
Villejuif, 94807, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?